Scott Bizily - 16 Feb 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role
Chief Legal Officer
Signature
By: /s/ Scott Bizily
Issuer symbol
FDMT
Transactions as of
16 Feb 2024
Net transactions value
-$35,128
Form type
4
Filing time
21 Feb 2024, 17:41:01 UTC
Previous filing
12 Feb 2024
Next filing
29 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $3,245 +500 +29% $6.49 2,237 16 Feb 2024 Direct F1
transaction FDMT Common Stock Options Exercise $10,050 +1,250 +56% $8.04 3,487 16 Feb 2024 Direct F1
transaction FDMT Common Stock Sale $48,422 -1,750 -50% $27.67 1,737 16 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -500 -2.9% $0.000000 16,543 16 Feb 2024 Common Stock 500 $6.49 Direct F1, F2
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -1,250 -2.7% $0.000000 44,584 16 Feb 2024 Common Stock 1,250 $8.04 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
F2 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F3 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.